Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.47 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449212 | 1.00 | KEAP1 (0.55) | KEAP1L3MBTL1NFE2L2KMT2AEP300 | |
| Hydrochloric Acid SCHEMBL8118011 | 0.98 | KEAP1 (0.53) | KEAP1L3MBTL1NFE2L2KMT2AEP300 | |
| SCHEMBL29904739 | 0.84 | KEAP1 (0.65) | KEAP1L3MBTL1NFE2L2KMT2AEP300 | |
| SCHEMBL2068498 | 0.84 | KEAP1 (0.65) | KEAP1L3MBTL1NFE2L2KMT2AEP300 | |
| SCHEMBL3962709 | 0.82 | KEAP1 (0.67) | KEAP1L3MBTL1NFE2L2KMT2APLA2G7 | |
| SCHEMBL21870755 | 0.80 | KEAP1 (0.50) | KEAP1L3MBTL1NFE2L2KMT2AEP300 | |
| SCHEMBL4090066 | 0.80 | KEAP1 (0.50) | KEAP1L3MBTL1NFE2L2KMT2APLA2G7 | |
| SCHEMBL19439099 | 0.80 | CA2 (0.52) | KMT2AGAAALOX15KDM4EMAPT | |
| SCHEMBL11722241 | 0.79 | PSIP1 (0.61) | KMT2AGAANR3C1NR3C2HTT | |
| SCHEMBL10695718 | 0.78 | HDAC3 (0.46) | KMT2AGAAALOX15KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697993-B | Pyrimidine compounds as AXL inhibitors | 南京正大天晴制药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-117736198-A | Macrocyclic nitrogen crown ether compounds and their use as protein kinase inhibitors | 科辉智药生物科技(深圳)有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-4200284-A1 | LMO2 PROTEIN INHIBITORS | University of Oxford (GB) | 2023-06-28 | — | — | EP | disclosed |
| CN-116283954-A | Hydroxamate compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-114901656-B | Hydroximic acid ester compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115697993-A | Pyrimidines as AXL inhibitors | 南京正大天晴制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022211573-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 테라펙스 | 2022-10-06 | — | — | WO | disclosed |
| CN-114901656-A | Hydroximic acid ester compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022170164-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022117016-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳微芯生物科技股份有限公司 | 2022-06-09 | — | — | WO | disclosed |
| WO-2022038356-A1 | LMO2 PROTEIN INHIBITORS | UNIVERSITY OF OXFORD (GB) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TYK2, WEE2, WEE1 | KEAP1 1439/4885L3MBTL1 4252/4885NFE2L2 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.